Revisiting Interleukin-12 as a Cancer Immunotherapy Agent. Scientific Publication

Jun 15, 2018 | Magazine: Clinical Cancer Research

Pedro Berraondo, Iñaki Etxeberria, Mariano Ponz-Sarvise, Ignacio Melero

Abstract

IL12 antitumor activities are mediated by the activation of T and natural killer (NK) lymphocytes to produce IFNγ. Systemically, recombinant IL12 has a narrow therapeutic window that favors local delivery, for instance, by gene therapy approaches. IL12 is a powerful partner in immunotherapy combinations with checkpoint inhibitors and adoptive T-cell transfer.

CITATION Clin Cancer Res. 2018 Jun 15;24(12):2716-2718. doi: 10.1158/1078-0432.CCR-18-0381. Epub 2018 Mar 16.

see publication in pubmed

Our authors

Dr. Pedro Berraondo López Curriculum

Researcher | Principal Investigator Cytokine-Based Therapeutics Research Group

Imagen del Dr. Mariano Ponz -Sarvisé, especialista en Oncología Médica de la Clínica Universidad de Navarra. El Dr. Ponz-Sarvisé se dedica preferencialmente a los tumores de páncreas y vías biliares.

Dr. Mariano Ponz-Sarvisé Curriculum

Researcher | Principal Investigator Solid Tumor Research Program

Imagen del Dr. Ignacio Melero Bermejo, especialista en Inmunología de la Clínica Universidad de Navarra.

Dr. Ignacio Melero Bermejo Curriculum

Researcher | Principal Investigator Combination Strategies for Translational Immunotherapy Research Group